Liquid biopsy is based on minimally invasive blood tests and has a high potential to significantly change the therapeutic strategy in cancer patients, providing an extremely powerful and reliable noninvasive clinical tool for the individual molecular profiling of patients in real time. Liquid biopsy approaches include the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating miRNAs, and tumor-derived extracellular vesicles (EVs) that are shed from primary tumors and their metastatic sites into peripheral blood. The major advantage of liquid biopsy analysis is that it is minimally invasive, and can be serially repeated, thus allowing extracting information from the tumor in real time. Moreover, the identification of predictive biomarkers in peripheral blood that can monitor response to therapy in real time holds a very strong potential for novel approaches in the therapeutic management of cancer patients. In this review, we summarize recent knowledge on CTCs and ctDNA and discuss future trends in the field. recently shown a significant potential for early cancer diagnosis and screening, 5 but it seems that it is still too early for establishment of peripheral blood assays for the early detection of cancer. 6 However, there are still many questions to be answered. 7 In this review, we summarize recent knowledge on CTCs and ctDNA and discuss future trends in the field.
| INTRODUCTION
Liquid biopsy is based on minimally invasive blood tests and has a high potential to significantly change the therapeutic strategy in cancer patients, providing an extremely powerful and reliable noninva- 
. The major advantage of liquid biopsy analysis is that it is minimally invasive, and can be serially repeated, thus allowing extracting information from the tumor in real time. Moreover, the identification of predictive biomarkers in peripheral blood that can monitor response to therapy in real time holds a very strong potential for novel approaches in the therapeutic management of cancer patients. 1, 2 CTC analysis presents nowadays a promising field for both advanced and early stage patients and CTC molecular characterization offers the unique potential to understand better the biology of metastasis and resistance to established therapies. 1, 2 In parallel, ctDNA analysis in plasma of cancer patients enables the identification of actionable genomic alterations, monitoring of treatment responses, unraveling therapeutic resistance, and potentially detecting disease progression before clinical confirmation. 3, 4 Liquid biopsy has also recently shown a significant potential for early cancer diagnosis and screening, 5 but it seems that it is still too early for establishment of peripheral blood assays for the early detection of cancer. 6 However, there are still many questions to be answered. 7 In this review, we summarize recent knowledge on CTCs and ctDNA and discuss future trends in the field.
| CIRCULATING TUMOR CELLS
The knowledge that tumor cells can travel through the vasculature to distant organ sites dates back to 1874, 8 while the presence of CTCs was first postulated in 1869 by Thomas Ashworth, who first described cells in the bloodstream that resembled those of tumors. 9 While in circulation, tumor cells have a short half-life and only a fraction survive to metastasize due to harsh conditions like apoptosis, elimination by the immune system, shear forces, and fluid turbulences. The "seed and soil" theory originally postulated by Stephen Paget and revisited by Langley and Fidler proposes that cancer cells (the seeds) have a preference to metastasize in a certain organ (the soil) seeking favorable conditions for their growth and development. 10 CTCs can undergo an epithelial to mesenchymal transition (EMT), which results in a significant change in cell phenotype through downregulation of epithelial markers and acquisition of mesenchymal properties, such as increased capacity for migration and invasion, causing disruption to basement and extracellular matrix. 11 EMT is not only a fundamental process in the metastatic cascade, as it enables disassociation of CTCs from the primary site, but furthermore has an important impact on CTC enrichment because the majority of analytical systems that detect CTCs are based on the expression of the epithelial marker EpCAM. 12 In this way, CTC subtypes lacking EpCAM expression but expressing mesenchymal markers can be missed unless EMT-related markers, such as TWIST and ALDH1, are used for their detection. 13 Mesenchymal CTCs have been associated with disease progression in breast cancer while their transition to the epithelial state through the opposite process, mesenchymal-epithelial transition (MET), plays a key role in allowing CTCs to seed in distant organs and establish metastasis. 12 
| Analytical systems for CTC isolation, enumeration, and detection
The identification and characterization of CTCs require extremely sensitive and specific analytical methodologies that include always a combination of enrichment and detection procedures.
1,2,14
The CellSearch system is still the only Food and Drug Administra- Size-based microfluidic devices enable CTC enrichment independently from the expression of specific antigens on their cell surface.
Using a label-independent device (Parsortix system, Angle PLC, Surrey, UK), 23, 24 in combination with a multimarker RNA profiling methodology for single CTCs, distinct CTC subsets were revealed. This approach provided important insights into gene regulatory networks relevant for cancer progression and therapy. 25 The same system when used in combination with single CTC analysis, revealed the heterogeneity of PIK3CA mutational status within patient-matched EpCAM high and EpCAM low/negative CTCs. 26 This isolation system offers great promise for the molecular characterization of CTCs as it is very efficient in removing contaminating cells. 27 The fluorescent EPISPOT assay is based on the identification of viable cells through the detection of pro- 40 Detection of CTCs using the CellSearch system before neoadjuvant therapy was an independent prognostic factor of impaired clinical outcome, and when combined with pathologic complete response (pCR), it was shown to be helpful to stratify breast cancer patients for therapeutic interventions. 41 In 3173 patients with nonmetastatic (stage I-III) breast cancer, the presence of CTCs was found to be an independent predictor of poor disease-free, overall, breast cancerspecific, and distant disease-free survival. 42 In a pooled analysis of two prospective trials in nonmetastatic inflammatory breast cancer, in patients treated with neoadjuvant chemotherapy combined with neoadjuvant and adjuvant bevacizumab, detection rate of CTC was 39% with a strong and independent prognostic value for survival, while combination of pCR after neoadjuvant treatment with no CTC detection at baseline isolated a subgroup of inflammatory breast cancer patients with excellent overall survival (OS), suggesting that CTC count could be part of inflammatory breast cancer stratification in prospective trials. 43 In the SUCCESS study, a multi-center, prospective, randomized trial, CTCs were detected in patients without signs of breast cancer recurrence when analyzed in peripheral blood using the FDA cleared CellSearch System 2 and 5 years after primary diagnosis. 44 According to the latest findings of the SUCCESS study, the presence of CTCs in high-risk early breast cancer patients during follow-up care suggests poor prognosis (E. Trapp et al, JNCI, in press). This finding is in full agreement with a previous study in which persistent detection of CK-19 mRNA-positive CTC during the first 5 years of follow-up was found to be associated with an increased risk of late relapse and death in patients with operable breast cancer and indicates the presence of chemotherapy and hormonotherapy-resistant residual disease. 45 According to very recent data based on a large cohort of breast cancer patients, CTC status is predictive of radiotherapeutic benefit in early-stage breast cancer. More specifically, treatment with radiotherapy was associated with longer disease free survival (DFS), and overall survival (OS) in patients with early-stage breast cancer and detectable
CTCs. 46 CTC clusters might provide an additional prognostic value when compared to CTC enumeration alone, in patients with elevated CTCs.
In a recent time-dependent analysis of longitudinally collected CTCs and CTC clusters, the presence of these clusters added additional prognostic values to CTC enumeration, and it was shown that the detection of larger size CTC clusters conferred a higher risk of death in metastatic breast cancer patients. 47 The additional prognostic value of CTC clusters appeared to be more pronounced in patients with inflammatory breast cancer, the most aggressive form of breast cancer with the poorest survival. 48 Recent studies that focused on the molecular characterization of
CTCs have revealed important information that could be further used for the benefit of breast cancer patients. Apoptotic CTCs have been detected in patients with breast cancer irrespective of their clinical status, and their incidence of detection is higher in early compared with metastatic patients. 49 It was also reported that the apoptotic index of CTCs is increased during clinical dormancy, whereas the proliferation index is increased on relapse. In addition, apoptotic CTCs are more frequently encountered during follow-up in dormancy candidate patients who remain disease free compared to those with subsequent late relapse, suggesting that monitoring proliferation and apoptosis in CTCs during clinical dormancy merits further investigation as a tool for predicting late disease recurrence. 50 A recent study has shown that in metastatic breast cancer, intact and apoptotic CTC are predictive of outcome, and therefore separate enumeration of intact CTC and apoptotic CTC is useful in tailoring systemic treatment. 51 Patients with a continuous presence of apoptotic or clustered CTCs in follow-up samples after systemic therapy initiation had worse prognosis than patients without these CTC characteristics. In patients with ≥5 CTC/7.5 mL blood at baseline, morphologic characterization of persistent CTCs could be an important prognostic marker during treatment, in addition to CTC enumeration alone. 52 It was also recently reported that mitotic CTCs are relativity common in aggressive late-stage breast cancer and may significantly correlate with shortened OS. CTCs in HER2 nonamplified nonmetastatic breast cancer. 55 The striking differences observed between these two clinical trials may be due to the different methodologies used for CTC detection; the one conducted by Georgoulias et al 44 was based on an EpCAM-independent molecular assay for CTC detection, while the one conducted by Ignatiadis et al 45 was based on EpCAM-positive CTCs that were also HER2 positive. Another recent study has shown that HER2 status on
CTCs was not only different from that of tumor tissues but it could also predict a different outcome of the patients' anti-HER2 therapy. 60 Very recently, using digital PCR, the presence of ESR1 mutations was evaluated in CTCs and matched cfDNA in patients with metastatic breast cancer, starting first-line endocrine therapy and progressing on any line of endocrine therapy; according to the data presented in this study, sensitivity for detecting ESR1 mutations in CTC-enriched fractions was lower than for cfDNA. 61 A recent study has shown that beyond ESR1 mutations, ESR1 gene can be epigenetically silenced in CTCs through DNA methylation, and that this was strongly associated with lack of response to everolimus/exemestane regimen. 62 Besides ER, recent data have shown that AR expression in CTCs of breast cancer patients is associated with bone metastases, suggesting that therapeutic targeting of AR could offer a potential benefit for patients with metastatic breast cancer. 63 Recently, the successful application of immune checkpoint regulators such as PD-L1 in the clinic may ultimately benefit from appropriate patient selection based upon predictive biomarkers. Cancer immunotherapies based on these targets often lead to long lasting remissions in patients with advanced malignancies; however, their high cost and toxicity profiles impose the necessity of developing predictive biomarkers able to discriminate responders from nonresponders. PD-L1 expression on CTCs was evaluated for the first time in 2015 in patients with breast cancer, and it was reported that it is frequently expressed in a subset of CTCs in metastatic breast cancer patients. 64 The clinical utility of CTC analysis in breast cancer is summarized in Table 1 .
| Prostate cancer
CTC enumeration and molecular characterization play a very important role in the clinical management of PCa patients and are giving important information toward understanding the biology of residual or relapsing PCa after local therapy. 65 The CellSearch system (CS) that is based on CTC enumeration is at present the only CTC assay cleared by the FDA for use in patients with metastatic PCa. 66 In a recent study aimed to improve CTC detection in nonmetastatic PCa patients by combining three independent CTC assays (CellSearch system, CellCollector, and the EPISPOT), the cumulative positivity rate of the three CTC assays was 81.3% (87/107) with 21.5% (23/107) of patients harboring ≥5 CTCs/7.5 mL blood. enzalutamide. 70 However, another study has shown that the response to cabazitaxel seems to be independent of the AR-V7 status of CTCs in mCRPC patients. 71 At the single-cell level, differential expression of AR-V7 between subgroups of CTCs in individual patients with PCa has been shown. 25 Padlock probe technology that is easily applicable in routine laboratories and compatible with multiple CTC-isolation devices enables quantification of AR-V7, AR-FL, PSA, and KRAS mut/wt transcripts in CTCs. 72 Recently, it was also shown that a biomarker panel containing CTC number and lactate dehydrogenase (LDH) levels was a surrogate for survival at the individual patient level in a clinical trial of abiraterone acetate plus prednisone vs prednisone alone for patients with metastatic CRPC. 73 Analysis of CTC gene expression revealed a clinically prognostic "liquid biopsy" signature in patients with metastatic castrate-resistance
PCa. 74 The validation of molecular assays in PCa is thus very important, especially for the detection of AR mutations, 75 gene expression, 76, 77 or RNA in situ hybridization 78 ; high analytical sensitivity, precision, specificity, and accuracy are thus extremely important for applications in the daily clinical practice.
AR-positive and CD45-negative circulating cells that are CKnegative/weak have also been detected using the CellSearch platform. 79 In a very recent study, it was shown that cell-surface vimentin-guided CTC enumeration may hold prognostic value and should be further validated as a possible measurement of PCa progression toward the deadly androgen-independent form. 80 The combination of in vivo CTC isolation with downstream RNA analysis is highly promising as a high-throughput, specific, and ultrasensitive approach for multiplex liquid biopsy-based molecular diagnostics for PCa patients. 22 The clinical utility of CTC analysis in PCa is summarized in Table 2 .
3 | CIRCULATING TUMOR DNA ctDNA harbors specific mutations that have occurred in primary and/or secondary tumors. During tumor evolution, new arising subclones result in differences in specific aberrations between the primary tumor and metastases. 83 Consequently, marker investigations at multiple time points provide a valuable tool for investigation of drug resistance as they represent a true signature of the mutational landscape at a given time, representing also tumor heterogeneity. ctDNA can serve as a surrogate marker for tumor burden in several types of cancer. 4, 85 ctDNA analysis is very promising even for early cancer detection. 86 Recently, a newly developed blood test, called CancerSEEK, can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. 5 However, the sensitivity for some tumor types such as breast cancer and for the detection of early tumors was rather low. Another study has also shown that ctDNA-based screening and MRD detection mainly based on NGS is challenging for early stage non-small cell lung cancer (NSCLC). 87 Plasma ctDNA analysis is appealing due to the ease with which plasma can be collected and analyzed without the prior need to enrich and isolate a rare population of cells. However, the fraction of tumorderived cell-free DNA is low and the background of cell-free DNA derived from apoptotic normal cells can vary from patient to patient and between two time points of blood analysis. The analysis of ctDNA can be also applied as a high-throughput strategy for the assessment of clinical samples, but it is limited to the analysis of point mutations, structural rearrangements, copy number aberrations, and changes in DNA methylation. EGFR mutations in cfDNA isolated from plasma of patients with NSCLC can stratify patients who may benefit from Up to now, however, there are a very limited number of studies in which CTCs are directly compared with ctDNA, using the same blood draws and the same biomarkers. 90 In a recent study, the utility of combining CTC and ctDNA to predict prognosis in metastatic breast cancer was evaluated retrospectively in 91 patients. CTCs were enumerated by CellSearch; the plasma-based assay was performed utilizing Guardant360 and the survival analysis using Kaplan-Meier curves.
The study demonstrated that a comprehensive liquid biopsy approach is a very effective prognostic tool. 91 In breast cancer, the sensitivity for detecting ESR1 mutations in CTC-enriched fractions was found lower than for cfDNA. 61 In NSCLC, cfDNA and CTCs are complementary, noninvasive assays for evaluation of acquired resistance to firstline EGFR TKIs and may expand the number of patients in whom actionable genetic information can be obtained at acquired resistance.
It was recently shown that serial cfDNA monitoring may offer greater clinical utility than serial monitoring of CTCs. 92 
| LIQUID BIOPSY AND EPIGENETICS
Liquid biopsy when combined with DNA methylation has a strong potential to provide a valuable source of circulating epigenetic biomarkers. DNA methylation patterns in plasma are currently gaining attention as they are known to arise early during cancer pathogenesis.
The methylation status of tumor and metastasis suppressor genes in
CTCs and ctDNA could be very informative, as it can be totally absent or detected at very low percentages in blood of healthy donors. The first report on epigenetic changes in CTCs was focused on SOX17 promoter methylation and demonstrated a close correlation between SOX17 methylation in CTCs and paired plasma ctDNA in patients with breast cancer. 90, 93 A detailed comparative study on epigenetic markers in paired primary tumors, CTCs, and plasma-ctDNA was also performed in breast cancer. 94 Another recent study from the same group has shown that ESR1 can be epigenetically silenced in CTCs through methylation, and that this not only reflects in paired plasma-ctDNA samples, but was also strongly associated with lack of response to everolimus/exemestane regimen. 62 Multigene methylation analysis of enriched CTCs can also provide prognostic information in metastatic breast cancer patients according to the results of a prospective proof of principle study that examined the quantitative methylation status of nine genes in CTCs enriched through a microfilter device. 95 DNA methylation analysis at the single-cell analysis revealed as expected an epigenetic heterogeneity among CTCs and indicated a tumor-specific active epigenetic regulation of EMT-associated genes during blood-borne dissemination. 96 
| QUALITY CONTROL AND PREANALYTICAL PARAMETERS IN LIQUID BIOPSIES
Assessing and controlling the preanalytical handling conditions of clinical samples is essential for downstream CTC analysis. 97 Preanalytical is not specifically designed for CTC analysis, as RNA is stabilized after lysis of all cells present in whole blood. 105, 106 Especially the reliability of gene expression studies in CTCs is affected by a variety of factors, because not only CTCs but mRNA as well is extremely fragile and sensitive. One important preanalytical factor is the time interval between PB draw from cancer patients and CTCs isolation, as the preservatives for cell fixation contained in tubes used for PB collection can severely affect the stability of CTC and especially CTC-mRNA. Thus, different anticoagulants and/or preservatives used in PB collection tubes may have distinct effects on CTCmRNA stability.
Commercially available cfDNA BCT blood collection tubes are claimed to stabilize nucleated blood cells, preventing the release of cellular DNA into plasma, and also inhibiting degradation of cfDNA. [107] [108] [109] [110] Commercially available cfRNA BCT blood collection tubes are also claimed to stabilize nucleated blood cells, preventing the release of cellular DNA into plasma, and also inhibiting degradation of cfRNA. Moreover, CTC molecular characterization provides a real-time monitoring of tumor evolution in cancer patients and could help to identify patients who might benefit from extra treatments, like chemotherapy, or targeted therapy after surgery, while it is valuable to evaluate heterogeneity and longitudinal monitoring of resistance to specific therapies.
On the other hand, ctDNA analysis requires a minimal amount of plasma (2 mL) and is logistically easier to assay than CTCs, however, this does not apply in cases where the goal is early detection of cancer. Its main advantages over CTC analysis is that ctDNA analysis is easily quantifiable, easier to assess tumor heterogeneity, it gives information on the mutational landscape of the tumor, it is highly diagnostic and prognostic, and can identify the presence of tumor. However, through this approach we get information only at the DNA level and we cannot identify metastasis occurring, as ctDNA can be derived both from necrotic and apoptotic cells. (https://www.cancer-id.eu/) (IMI contract no. 115749).
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